Skip to content
ZLAB·Nasdaq·US

Zai Lab

Zai Lab is a commercial-stage global biopharmaceutical company with a substantial presence in Greater China and the United States. It discovers, develops, and commercializes products for medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. It has seven commercial programs launched in Greater China, with sales and marketing teams covering major medical centers there.

Source: SEC 10-K Feb 26, 2026

Thematic Position

ZLAB

Relationship Groups

Suppliers5
Customers1
Partners5
Licensing9

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

dividend restrictionstatutory reserve requirementcapital restriction
Chinese laws and reserve requirements prevent subsidiary distributions to Zai Lab, restricting paid-in capital
SEC 10-KFeb 26, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.